Phase I/II Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Elotuzumab (Primary) ; Natural killer cell therapy (Primary) ; Autologous stem cell therapy; Filgrastim; Interleukin-2; Lenalidomide; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2024 Status changed from active, no longer recruiting to completed.
- 16 Apr 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 16 Apr 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.